Modafinil
- Generic Name
- Modafinil
- Brand Names
- Provigil
- Drug Type
- Small Molecule
- Chemical Formula
- C15H15NO2S
- CAS Number
- 68693-11-8
- Unique Ingredient Identifier
- R3UK8X3U3D
- Background
Modafinil is a stimulant drug marketed as a 'wakefulness promoting agent' and is one of the stimulants used in the treatment of narcolepsy. Narcolepsy is caused by dysfunction of a family of wakefulness-promoting and sleep-suppressing peptides, the orexins, whose neurons are activated by modafinil. The prexin neuron activation is associated with psychoactiva...
- Indication
To improve wakefulness in patients with excessive daytime sleepiness (EDS) associated with narcolepsy.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Fatigue, Major Depressive Disorder (MDD), Narcolepsy, Obstructive Sleep Apnea (OSA), Shift-work related sleep disturbance
- Associated Therapies
- -
Modafinil in Treating Children With Memory and Attention Problems Caused by Cancer Treatment for a Brain Tumor
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 112
- Registration Number
- NCT01381718
- Locations
- 🇺🇸
A. I. duPont Hospital for Children, Wilmington, Delaware, United States
🇺🇸Connecticut Children's Medical Center, Hartford, Connecticut, United States
🇺🇸Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
Effectiveness of Modafinil in Improving Cognitive Performance of University Students
- First Posted Date
- 2011-06-03
- Last Posted Date
- 2011-06-03
- Lead Sponsor
- Universidad de Valparaiso
- Target Recruit Count
- 128
- Registration Number
- NCT01365897
- Locations
- 🇨🇱
Escuela de Medicina, Universidad de Valparaiso, Valparaiso, V Region, Chile
🇨🇱Escuela de Psicología, Universidad de Valparaiso, Valparaiso, V Region, Chile
A Randomized, Placebo-Controlled Trial of Modafinil for Methamphetamine Dependence
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2013-07-02
- Target Recruit Count
- 72
- Registration Number
- NCT01354470
- Locations
- 🇺🇸
New Leaf Treatment Center, Lafayette, California, United States
🇺🇸CPMC Research Institute, St.Luke's Hospital, San Francisco, California, United States
Methylphenidate HCl or Modafinil in Treating Young Patients With Excessive Daytime Sleepiness After Cancer Therapy
- Conditions
- Interventions
- First Posted Date
- 2011-05-05
- Last Posted Date
- 2014-02-21
- Lead Sponsor
- University of South Florida
- Target Recruit Count
- 1
- Registration Number
- NCT01348607
Treatment of Apathy in Alzheimer's Disease With Modafinil
- First Posted Date
- 2010-07-29
- Last Posted Date
- 2011-03-04
- Lead Sponsor
- Brown University
- Target Recruit Count
- 22
- Registration Number
- NCT01172145
- Locations
- 🇺🇸
Butler Hospital, Providence, Rhode Island, United States
Modafinil, Sleep Architecture and Cocaine Relapse
- Conditions
- Interventions
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2016-04-27
- Lead Sponsor
- Yale University
- Target Recruit Count
- 114
- Registration Number
- NCT01137396
- Locations
- 🇺🇸
Connecticut Mental Health Center, New Haven, Connecticut, United States
Pharmacodynamics and Efficacy of MK-7288 in Adults With Sleep Apnea (MK-7288-010)
- Conditions
- Interventions
- First Posted Date
- 2010-03-25
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT01092780
Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia
- Conditions
- Interventions
- First Posted Date
- 2010-03-12
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 28
- Registration Number
- NCT01085903
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Conway Regional Rehabilitation Hospital, Conway, Arkansas, United States
Efficacy and Safety Study of BF2.649 in the Treatment of Excessive Daytime Sleepiness in Narcolepsy
- Conditions
- Interventions
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2012-06-11
- Lead Sponsor
- Bioprojet
- Target Recruit Count
- 110
- Registration Number
- NCT01067222
- Locations
- 🇨🇭
Neurocenter (EOC) of Southern Switzerland, Lugano, Switzerland
Acute Effect of Three Neuroactive Drugs Measured by Magnetoencephalography (MEG), Electroencephalography (EEG) and the Synchronous Neural Interaction Test
- Conditions
- Interventions
- First Posted Date
- 2009-09-09
- Last Posted Date
- 2010-01-13
- Lead Sponsor
- Orasi Medical, Inc.
- Target Recruit Count
- 15
- Registration Number
- NCT00972985
- Locations
- 🇺🇸
Alexian Brothers Neuroscience Institute, Elk Grove Village, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.